Abstract
Dupilumab, a monoclonal antibody that binds and inhibits the interleukin-4 receptor alpha subunit, is FDA approved for use in atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis. Currently, it is being investigated for treatment of conditions associated with eosinophilic inflammation. We present a case series of three patients with allergic rhinoconjunctivitis and recurrent episodes of glue ear otitis who had promising therapeutic relief with use of dupilumab. Patients had a multi-year history of chronic glue ear otitis with numerous medical and surgical interventions without resolution, including near systemic steroid dependence.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
